Company Overview

Soleno Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of novel therapies for rare diseases with significant unmet medical needs. The company operates within the biotechnology and rare disease therapeutics industries, with a primary emphasis on genetic disorders affecting metabolic and neurobehavioral function. Soleno’s core development program targets Prader-Willi syndrome (PWS), a rare and complex genetic condition characterized by hyperphagia, obesity, and behavioral challenges.

The company’s principal product candidate is DCCR (diazoxide choline) extended-release tablets, designed for chronic treatment of hyperphagia in individuals with PWS. Soleno is positioned as a single‑asset, development-stage biotechnology company, with its strategy centered on advancing DCCR through regulatory approval and, if approved, commercialization in the United States. The company traces its origins to Capnia, Inc., which merged with Essentialis, Inc. in 2017 and subsequently changed its name to Soleno Therapeutics, reflecting its strategic focus on rare diseases.

Business Operations

Soleno operates as a single reporting segment focused on drug development, clinical research, and regulatory advancement. Its business activities are concentrated on clinical trials, manufacturing readiness, regulatory submissions, and preparation for potential commercialization of DCCR. As of publicly available disclosures, the company does not generate commercial product revenue and funds operations primarily through equity financing.

Operations are primarily domestic, with clinical trial activities conducted at multiple investigational sites. Soleno relies on third-party contract research organizations and manufacturing partners rather than owning large-scale production assets. The company does not report material revenue from partnerships, licensing agreements, or international sales, and no major operating subsidiaries or joint ventures have been publicly disclosed.

Strategic Position & Investments

Soleno’s strategic direction is centered on becoming a leading rare disease company by delivering what it positions as the first pharmacologic treatment addressing hyperphagia in PWS. Its near-term growth strategy is tied almost entirely to the regulatory and clinical success of DCCR, including submission and review of regulatory filings and scaling commercial infrastructure if approval is obtained. The company has received regulatory designations intended to support development in rare diseases, which may include orphan drug-related benefits.

The company has not announced a diversified acquisition strategy or a broad pipeline beyond PWS. Investment activity has primarily involved funding late-stage clinical development, regulatory preparation, and intellectual property protection related to DCCR. Based on available public sources, involvement in additional therapeutic areas or emerging technologies beyond its lead program is limited, and data on pipeline expansion remains inconclusive.

Geographic Footprint

Soleno Therapeutics is headquartered in the United States, with its principal executive offices located in California. Its operational footprint is primarily U.S.-based, reflecting its focus on domestic clinical development and anticipated initial commercialization within the U.S. market.

International presence is limited and largely indirect, consisting mainly of clinical trial participation or regulatory considerations outside the U.S. The company does not report established commercial operations, offices, or manufacturing facilities across Europe, Asia-Pacific, or other global regions, and its international investment influence remains minimal based on current public disclosures.

Leadership & Governance

Soleno is led by an executive team with experience in pharmaceuticals, rare disease development, and public company governance. Leadership emphasizes disciplined clinical execution, regulatory engagement, and patient-focused development strategies tailored to rare genetic disorders.

Key executives include:

• Anish Bhatnagar, MD – President and Chief Executive Officer
• Todd Parker – Chief Financial Officer
• Michael D. Heffernan – Chief Operating Officer
• Mark J. Pykett, PhD – Chief Scientific Officer

The board and management team collectively guide corporate strategy, capital allocation, and long-term vision, with governance practices aligned to U.S. public company standards.